AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04188392
Drug: Pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pimavanserin tablet
Trial: NCT01448096
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
Trial: NCT00003160
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00738595
Drug: EVT 302
RxNorm normalized name: EVT 302
DrugBank: EVT 302 (DB06057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVT 302 5 mg once daily
Trial: NCT00738595
Drug: EVT 302 plus open label Nicotine replacement
RxNorm normalized name: ephedrine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind EVT 302 plus open label nicotine replacement
Trial: NCT00738595
Drug: Placebo plus open label Nicotine Replacement
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
Trial: NCT01119417
Drug: BQ123
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose day: 25 nmol/min, single IV infusion for 15 min.
Trial: NCT02066038
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
Trial: NCT01119417
Drug: BQ123
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose day: 50 nmol/min, single IV infusion for 15 min
Trial: NCT01119417
Drug: BQ123
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose day: 300 nmol/min, single IV infusion for 15 min.
Trial: NCT01119417
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-3 IV saline infusions for 15 min each.
Trial: NCT01423305
Drug: Budesonide/formoterol capsule.
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration with concomitant charcoal.
Trial: NCT01423305
Drug: Budesonide/formoterol capsule for oral adm.
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration without concomitant charcoal.
Trial: NCT02574637
Drug: Brazikumab IV Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Brazikumab (DB16115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazikumab IV infusion as per protocol specified dosing schedule.
Trial: NCT00045786
Drug: CC-1088
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
Trial: NCT02574637
Drug: Brazikumab SC Injection
RxNorm normalized name: Brazikumab
DrugBank: Brazikumab (DB16115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazikumab IV infusion as per protocol specified dosing schedule.
Trial: NCT00374309
Drug: VRC-EBOADV018-00-VP
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00859703
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35mg oral risedronate once per week for 24 months
Trial: NCT00835614
Drug: Cefprozil for oral suspension 250 mg/5 mL
RxNorm normalized name: cefprozil Oral Suspension
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Trial: NCT02927210
Drug: Dimethandrolone Undecanoate
RxNorm normalized name: Dimethandrolone Undecanoate
DrugBank: Dimethandrolone Undecanoate (DB16141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
Trial: NCT03164616
Drug: Pemetrexed + cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Trial: NCT00807495
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib capsules
Trial: NCT05406050
Drug: reference eldecalcitol soft capsule
RxNorm normalized name: Eldecalcitol
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
Trial: NCT05406050
Drug: test eldecalcitol soft capsule
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
Trial: NCT03822130
Drug: Arterial catheter infusion chemotherapy
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arterial catheter infusion chemotherapy
Trial: NCT03822130
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arterial catheter infusion Sodium Bicarbonate
Trial: NCT03822130
Drug: Systemic Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Chemotherapy
Trial: NCT03822130
Drug: Oral Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chemotherapy
Trial: NCT03434769
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25mg/m\^2 IV on days -5 to -3
Trial: NCT00006479
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00662792
Drug: Tiotropium (Tio18GEL)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 µg Tiotropium (Tio18GEL) inhalation powder
Trial: NCT00662792
Drug: Salmeterol MDPI (Salm50DPI)
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
Trial: NCT00148018
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00148018
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01378949
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% with adrenaline 5 mcg/cc
Trial: NCT01378949
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg/cc
Trial: NCT01835587
Drug: CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
Trial: NCT00662792
Drug: Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)
Trial: NCT01174186
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Trial: NCT02535988
Drug: Thymalfasin
RxNorm normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
Trial: NCT02639143
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02639143
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02784808
Drug: Biological DMARDs
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
Trial: NCT00724360
Drug: Herceptin (trastuzumab)
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
Trial: NCT01066858
Drug: Tenofovir disoproxil fumarate (TDF)
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
Trial: NCT02502448
Drug: hydroxyethyl starch (HES 130/0.6)
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00287820
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine 5-40 mg/day
Trial: NCT00662792
Drug: Tiotropium/Salmeterol (T+S_PE)
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder
Trial: NCT04212650
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
Trial: NCT04655898
Drug: [14C]CC-90001
DrugBank: CC-90001 (DB18445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00287820
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine 5-40 ,mg/day
Trial: NCT00287820
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: risperidone 1-12 mg/day
Trial: NCT03095352
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
Trial: NCT04235114
Drug: 50 mg 89Zr-DFO-Nimotuzumab
RxNorm normalized name: DFO
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
Trial: NCT04235114
Drug: 1 mg 89Zr-DFO-Nimotuzumab
RxNorm normalized name: DFO
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
Trial: NCT04557878
Drug: Hypertonic Dextrose Solution
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
Trial: NCT02071121
Drug: 14C-BIIB061
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
Trial: NCT01580618
Drug: TNK (Tenecteplase)
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
Trial: NCT01370811
Drug: oxybutynin and clonidine oral solution treatment A
RxNorm normalized name: oxybutynin Oral Solution
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04324840
Drug: CC-90010
RxNorm normalized name: Bet inhibitor cc-90010
DrugBank: Trotabresib (DB17421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04324840
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT01370811
Drug: oxybutynin and clonidine oral solution treatment B
RxNorm normalized name: oxybutynin Oral Solution
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01370811
Drug: oxybutynin and clonidine oral solution treatment C
RxNorm normalized name: oxybutynin Oral Solution
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01370811
Drug: oxybutynin and clonidine oral solution treatment D
RxNorm normalized name: oxybutynin Oral Solution
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01906372
Drug: Adrenocorticotropic Hormone Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
Trial: NCT00044278
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03919799
Drug: Belumosudil (KD025)
RxNorm normalized name: belumosudil
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ROCK-2 Inhibitor
Trial: NCT00382577
Drug: Itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01433614
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 i.v. every 3 weeks, both study arms
Trial: NCT01433614
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
Trial: NCT03329573
Drug: Paroxetine IR tablets A
RxNorm normalized name: paroxetine Oral Tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
Trial: NCT03329573
Drug: Paroxetine IR tablets B
RxNorm normalized name: paroxetine Oral Tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
Trial: NCT01031355
Drug: Estradiol Valerate (EV) (BAY86-4980)
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
Trial: NCT01031355
Drug: Levomefolate Calcium (BAY86-7660)
RxNorm normalized name: Levomefolate Calcium
DrugBank: Levomefolic acid (DB11256)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
Trial: NCT00088478
Drug: Intramuscular Olanzapine Depot
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03951402
Drug: 100 mg CG5503 (tapentadol hydrochloride) PR tablet
RxNorm normalized name: tapentadol
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg CG5503 (tapentadol hydrochloride) PR tablet.
Trial: NCT03951402
Drug: Placebo matching moxifloxacin capsule
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule to moxifloxacin capsule.
Trial: NCT03951402
Drug: 400 mg Moxifloxacin tablet (overencapsulated)
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overencapsulated 400 mg Moxifloxacin tablet.
Trial: NCT00465205
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg oral twice daily
Trial: NCT01423058
Drug: Momelotinib
RxNorm normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles.
Trial: NCT02272686
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 560 mg by mouth daily.
Trial: NCT01707615
Drug: GSPE
RxNorm normalized name: Grape Seed Proanthocyanidin Extract
DrugBank: Grape (DB10533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSPE 240 mg/day (120mg bid)
Trial: NCT01212185
Drug: intranasal oxytocin spray
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
Trial: NCT01482884
Drug: tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 sc injections of every 2 weeks for 12 weeks.
Trial: NCT03222349
Drug: Diazepam Buccal Film
RxNorm normalized name: diazepam Buccal Film
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
Trial: NCT03119584
Drug: linaclotide or placebo
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01234298
Drug: SPD489 Low-Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
Trial: NCT03629054
Drug: Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose
Trial: NCT03629054
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose
Trial: NCT03629054
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose
Trial: NCT03629054
Drug: Metformin HCl
RxNorm normalized name: metformin HCl
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose
Trial: NCT01831193
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00439244
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days.
Trial: NCT00070174
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00070174
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes